Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

7 Signs Your 401(k) Is Quietly Underperforming

View original at finance.yahoo.com
7 Signs Your 401(k) Is Quietly Underperforming Quick Read iShares Core S&P 500 ETF (IVV) charges an expense ratio of 0.03%, the benchmark for low-cost index investing, while many 401(k) plans offer index-style funds charging over 0.5%—a gap that compounds into six-figure losses on a $500,000 balance over 20 years…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Staying in a low-yielding default option while equity markets compound is one of the most expensive passive decisions a retirement saver can make

    60% confidence
  • Target-date funds from high-fee providers charge 0.6% to 0.8% annually compared to under 0.15% for low-cost alternatives

    60% confidence
  • Most 401(k) account holders unknowingly lose wealth through structural problems like excessive fees, concentrated employer stock positions above 10%, drift from target allocations, and failure to rebalance—costing participants tens of thousands in foregone compounding

    60% confidence
  • Actively managed funds charge more and, over long periods, most underperform their benchmark indexes after fees

    60% confidence
  • Many 401(k) plans offer index-style funds charging over 0.5%, a gap that compounds into six-figure losses on a $500,000 balance over 20 years compared to iShares Core S&P 500 ETF's 0.03% expense ratio

    60% confidence
  • A $100,000 investment at a 7% gross annual return can grow substantially over 20 years at near-zero fees, while a 1% expense ratio meaningfully reduces that outcome

    60% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · federal funds rate3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
7 Signs Your 401(k) Is Quietly Underperforming — Source | Via News | Finance Via News